FAQ: Quantum BioPharma Appoints Dr. Jack Antel as Clinical Advisor for MS Program
Summary
Quantum BioPharma has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert, as clinical advisor to support the development of Lucid-MS, their investigational drug for MS. This appointment strengthens the company's clinical expertise as they advance Lucid-MS into Phase 2 studies.
What is the main announcement in this content?
Quantum BioPharma has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support the development of Lucid-21-302 (Lucid-MS), their patented investigational drug for multiple sclerosis.
Who is Dr. Jack Antel and why is his appointment significant?
Dr. Jack Antel is a world-renowned MS expert, Professor of Neurology at McGill University, and recipient of the National Multiple Sclerosis Society and American Academy of Neurology’s Dystel Award with over 450 published articles. His expertise will guide the design of efficacy trials as Quantum advances Lucid-MS into Phase 2 studies.
What is Lucid-MS and how does it work?
Lucid-MS is Quantum BioPharma’s patented investigational drug designed to inhibit demyelination in multiple sclerosis. It is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What stage of development is Lucid-MS currently in?
Quantum BioPharma is advancing Lucid-MS into Phase 2 studies, with Dr. Antel joining to guide the design of efficacy trials for this next phase of clinical development.
What other clinical advisors are involved in the MS program?
Dr. Antel joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor for Quantum BioPharma’s MS program.
What other areas does Quantum BioPharma focus on besides MS?
Quantum BioPharma is dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% rights for pharmaceutical and medical uses.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/
What is the full press release link mentioned in the content?
To view the full press release, visit https://ibn.fm/NWMFj as referenced in the content.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 240505